---
title: "內克塔治療公司首席執行官 Howard W. Robin 報告了出售普通股的情況"
description: "內克塔治療首席執行官霍華德·W·羅賓報告處置普通股。內克塔治療的總裁兼首席執行官霍華德·W·羅賓報告了對公司普通股的處置。完整的文件可以通過以下鏈接訪問"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/241316597.md"
published_at: "2025-05-22T00:07:37.000Z"
---

# 內克塔治療公司首席執行官 Howard W. Robin 報告了出售普通股的情況

> 內克塔治療首席執行官霍華德·W·羅賓報告處置普通股。內克塔治療的總裁兼首席執行官霍華德·W·羅賓報告了對公司普通股的處置。完整的文件可以通過以下鏈接訪問

內克塔治療首席執行官霍華德·W·羅賓報告處置普通股

內克塔治療的總裁兼首席執行官霍華德·W·羅賓報告了對公司普通股的處置。完整的文件可以通過以下鏈接訪問。

### Related Stocks

- [NKTR.US - 內克塔治療](https://longbridge.com/zh-HK/quote/NKTR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Nektar Therapeutics eases after boosted $400 mln share sale | Nektar Therapeuticsshares fell 5.6% premarket to $62.63 after a $400 million equity raise, selling approximately 6.9 mil | [Link](https://longbridge.com/zh-HK/news/275769952.md) |
| Nekkar ASA completes share buy-back transactions totaling NOK 46,339,911 | Nekkar ASA has completed share buy-back transactions totaling NOK 46,339,911 under its renewed program, managed by an in | [Link](https://longbridge.com/zh-HK/news/275292221.md) |
| BUZZ-Nektar Therapeutics launches $300 mln equity offering after stock soars | Nektar Therapeuticsis launching a $300 million equity offering following a 51.1% surge in its stock price, closing at $5 | [Link](https://longbridge.com/zh-HK/news/275514120.md) |
| Nektar Therapeutics kündigt Phase-2b-Studie mit Rezpegaldesleukin bei atopischer Dermatitis an | Nektar Therapeutics has announced the upcoming presentation of topline results from the ongoing Phase 2b study REZOLVE-A | [Link](https://longbridge.com/zh-HK/news/275363082.md) |
| Nekkar ASA Completes Share Buy-Backs Worth NOK 44.65 Million | Nekkar ASA has completed share buy-backs worth NOK 44.65 million, repurchasing 58,577 shares at an average price of NOK  | [Link](https://longbridge.com/zh-HK/news/273663404.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。